Literature DB >> 34328582

Gene expression profiling of 19q-loss astrocytomas suggest a specific pattern associated with the better prognosis.

Ryohei Otani1,2, Akitake Mukasa3, Takeo Uzuka4, Fumi Higuchi4, Hadzki Matsuda4, Masashi Nomura5, Shota Tanaka5, Phyo Kim4, Keisuke Ueki4.   

Abstract

PURPOSE: We previously reported that there was a subgroup of IDH-mutated astrocytomas harboring only 19q-loss showing oligodendroglioma-like morphology and significantly longer overall survival (OS) compared with 19q-intact astrocytomas. The aim of this study was to further explore the biological characteristics of this possible subgroup and obtain insight into the mechanism of their relatively benign clinical behavior.
METHODS: We compared gene expression pattern between five 19q-loss and five 19q-intact IDH-mutated astrocytomas by microarray analysis.
RESULTS: By comparing expression levels of genes of 19q-loss astrocytomas to those of 19q-intact astrocytomas, 102 up-regulated genes and 162 down-regulated genes were extracted. The down-regulated genes clustered heavily to 19q and 4p while the up-regulated genes clustered to 4q. It was noteworthy that fibroblast growth factor 1 associated with stem cell maintenance and multiple genes associated with glioma progression were down-regulated in 19q-loss astrocytomas, and these results were validated with the independent TCGA data set. On t-SNE analysis of the 19q-loss astrocytomas with other IDH-mutant glioma subgroups from the TCGA datasets, the expression pattern of the 19q-loss astrocytomas showed no shift toward oligodendrogliomas with 1p/19q codeletion but rather constituted a subgroup of astrocytoma.
CONCLUSIONS: These findings suggested that 19q-loss in astrocytomas is more likely acquired event rather than an early event in oncogenesis like the 1p/19q-codeletion in oligodendrogliomas, and that the biological features of 19q-loss astrocytomas are possibly related to differentially expressed genes associated with stem cell maintenance and glioma progression.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  19q; Genomics; Glioma; Heterogeneity; Microarray

Mesh:

Year:  2021        PMID: 34328582     DOI: 10.1007/s11060-021-03816-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  15 in total

1.  Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq.

Authors:  Andrew S Venteicher; Itay Tirosh; Christine Hebert; Keren Yizhak; Cyril Neftel; Mariella G Filbin; Volker Hovestadt; Leah E Escalante; McKenzie L Shaw; Christopher Rodman; Shawn M Gillespie; Danielle Dionne; Christina C Luo; Hiranmayi Ravichandran; Ravindra Mylvaganam; Christopher Mount; Maristela L Onozato; Brian V Nahed; Hiroaki Wakimoto; William T Curry; A John Iafrate; Miguel N Rivera; Matthew P Frosch; Todd R Golub; Priscilla K Brastianos; Gad Getz; Anoop P Patel; Michelle Monje; Daniel P Cahill; Orit Rozenblatt-Rosen; David N Louis; Bradley E Bernstein; Aviv Regev; Mario L Suvà
Journal:  Science       Date:  2017-03-31       Impact factor: 47.728

Review 2.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

3.  Tumorigenesis in transgenic mice in which the SV40 T antigen is driven by the brain-specific FGF1 promoter.

Authors:  I M Chiu; K Touhalisky; Y Liu; A Yates; A Frostholm
Journal:  Oncogene       Date:  2000-12-14       Impact factor: 9.867

4.  Expression of EGF receptor and FGF receptor isoforms during neuroepithelial stem cell differentiation.

Authors:  A J Kalyani; T Mujtaba; M S Rao
Journal:  J Neurobiol       Date:  1999-02-05

5.  Knockdown of long non-coding RNA HOTAIR inhibits malignant biological behaviors of human glioma cells via modulation of miR-326.

Authors:  Jing Ke; Yi-long Yao; Jian Zheng; Ping Wang; Yun-hui Liu; Jun Ma; Zhen Li; Xiao-bai Liu; Zhi-qing Li; Zhen-hua Wang; Yi-xue Xue
Journal:  Oncotarget       Date:  2015-09-08

6.  Humanization of fibroblast growth factor 1 single-chain antibody and validation for its antitumorigenic efficacy in breast cancer and glioma cells.

Authors:  Xiao-Xiao He; Shuang Du; Shi-Qian Gao; Jing-Ying Chen; Ran-Juan Cao; Zhen-Kai Xing; Alia Rizvi Syeda Kazim; Hua-Li Yu; Qing-Chuan Zheng; Xiao-Juan Zhu
Journal:  J Cell Mol Med       Date:  2018-03-24       Impact factor: 5.310

7.  Capture at the single cell level of metabolic modules distinguishing aggressive and indolent glioblastoma cells.

Authors:  Mirca S Saurty-Seerunghen; Léa Bellenger; Elias A El-Habr; Virgile Delaunay; Delphine Garnier; Hervé Chneiweiss; Christophe Antoniewski; Ghislaine Morvan-Dubois; Marie-Pierre Junier
Journal:  Acta Neuropathol Commun       Date:  2019-10-16       Impact factor: 7.801

8.  Activation of Aurora A kinase through the FGF1/FGFR signaling axis sustains the stem cell characteristics of glioblastoma cells.

Authors:  Yi-Chao Hsu; Chien-Yu Kao; Yu-Fen Chung; Don-Ching Lee; Jen-Wei Liu; Ing-Ming Chiu
Journal:  Exp Cell Res       Date:  2016-04-30       Impact factor: 3.905

9.  Oligodendrocyte Progenitor Cells and Macrophages/Microglia Produce Glioma Stem Cell Niches at the Tumor Border.

Authors:  Takuichiro Hide; Yoshihiro Komohara; Yuko Miyasato; Hideo Nakamura; Keishi Makino; Motohiro Takeya; Jun-Ichi Kuratsu; Akitake Mukasa; Shigetoshi Yano
Journal:  EBioMedicine       Date:  2018-03-01       Impact factor: 8.143

10.  IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.

Authors:  Ryohei Otani; Takeo Uzuka; Fumi Higuchi; Hadzki Matsuda; Masashi Nomura; Shota Tanaka; Akitake Mukasa; Koichi Ichimura; Phyo Kim; Keisuke Ueki
Journal:  Cancer Sci       Date:  2018-06-15       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.